International Faculty
Below are the International Faculty for 2025.
Prof Anita Asgar
Dr Anita Asgar is an Interventional Cardiologist working at the Montreal Heart Institute since 2009. Originally from Newfoundland, Dr. Asgar completed her medical school and Internal Medicine Residency at Memorial University (1995-2002), and Cardiology training at Dalhousie University. She then completed a two-year fellowship in Interventional Cardiology at the Institut de Cardiologie de Montreal, followed by a fellowship in Structural and Congenital Intervention at the Royal Brompton Hospital in London, England as well as a fellowship in Cardiac Magnetic Resonance Imaging. She has a master’s degree in Biomedical Sciences from the Universite de Montreal with a focus in cost-effectiveness of medical technology.
Dr. Anita Asgar has been a full-time staff Interventional Cardiologist at the Montreal Heart Institute, and Associate Professor of Medicine at the Universite de Montreal. She specializes in transcatheter valve interventions, congenital interventions and cardiac MRI. Dr. Asgar was Co-Chair of the Canadian TAVR Guidelines and chaired the Working Group for Transcatheter Valve Therapy Quality Indicators in Canada. She is currently Co-Chair of the Canadian Clinical Position Update on Mitral and Tricuspid valve interventions and is the Editor of two E-books on mitral and tricuspid Transcatheter Edge to Edge Repair for SCAI. She is currently the Medical Director of the Structural Heart Program at the Montreal Heart Institute since 2022 but will be leaving to join Northwestern Medicine in Chicago, Illinois as Section Chief of Interventional Cardiology and System Medical Director of Structural Interventions in January 2025. Her research interests include the treatment and management of valvular heart disease and innovation in structural heart interventions.
Close
Prof. Eberhard Grube
Prof. Eberhard Grube
Professor Eberhard Grube is Professor of Medicine, Head, Center of Innovative Interventions in Cardiology (CIIC) University Hospital Bonn, Germany and Consulting Professor, Division of Cardiovascular Medicine, at Stanford University School of Medicine and Consulting Professor of the INCOR Heart Institute of the University of Sao Paulo, Brazil.
Professor Grube received his first degree in Medicine at the Rheinische Friedrich- Wilhelm-University in Bonn. His cardiology training was completed at University of Wisconsin, Medical School and University of Bonn, Medical School. Prof Grube received his Board Certification in Internal Medicine, in Cardiology and in Angiology from the North Rhine Chamber of Medical Doctors and his post-doctoral lecturing qualification “Internal Medicine” from the Rheinische Friedrich-Wilhelm-University in Bonn.
Prof Grube is a fellow of the American College of Cardiology, the American College of Angiology and the Society for Cardiac Angiography & Interventions. His research interests include drug eluting stents, distal protection devices, debulking devices, restenosis and in-stent restenosis as well as structural heart disease in particular transcatheter therapy of aortic and mitral diseases.
Close
Dr. Kentaro Hayashida
Dr. Kentaro Hayashida
Dr. Kentaro Hayashida graduated from Keio University School of Medicine of Tokyo in 2000. He was a fellow in Massy, France between 2009-2012. He is currently working as the director of the cardiac catheterization laboratory and the transcatheter heart valve program at Keio University. His main research interest includes transcatheter intervention for structural heart disease and he founded the OCEAN-SHD family in 2013 to organize a multicenter research platform in Japan.
He is also a founder and course director of PCR Tokyo valves, a leading conference in the Asia-Pacific region in the field of transcatheter heart valve therapy. He is serving as the editor-in-chief of the journal of transcatheter valvular therapeutics. He is a fellow of the European society of cardiology (FESC), the American college of cardiology (FACC), and the Japanese society of cardiology (FJCS). He is also proctoring for TAVI (Edwards Lifesciences, Medtronic, and Abbott) and MTEER (Abbott).
Close
Prof. Saibal Kar
Prof. Saibal Kar
Professor Saibal Kar, MD, FACC, FSCAI, is a board-certified interventional cardiologist in Thousand Oaks, CA. He serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System. An astute clinician and teacher with a special expertise in interventions for structural heart disease, he is a Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA. In his present position he directs important clinical trials involving structural heart disease interventions in the hospital, and at a national level.
Dr. Kar focuses his research on coronary restenosis, device development, and the advancement of percutaneous techniques in the treatment of structural heart disease. He is recognized internationally for his research and clinical experience in transcatheter mitral valve repair, as well as transcatheter treatment options for prevention of cardioembolic stroke. In the preclinical lab, he has helped develop novel drug-eluting stents that are currently being used in clinical practice.
Dr. Kar’s work has been published in more than 150 peer-reviewed publications and textbooks. He has delivered more than 200 lectures in national and international conferences all around the globe. He serves as a reviewer for a number of preeminent cardiology journals and is on the editorial board of several journals as well. He is a fellow and active member of the American College of Cardiology, Society of Coronary Angiography and Intervention, and the Cardiac Society of India.
Dr. Kar is gifted operator and teacher and mentor for several cardiologists all around the World. He has taught physicians all around the World to perform transcatheter mitral valve repair, left atrial appendage occlusion and several other structural heart disease procedures. Dr. Kar earned his medical degree from Nil Ratan Sircar Medical College in Kolkata, India. Following his internship, he completed his residency in medicine and his fellowship in cardiology at the Postgraduate Institute of Medical Education and Research in Chandigarh, India.
He was also an interventional cardiology fellow at the Epworth Hospital in Melbourne, Australia. In the United States, Dr. Kar repeated his residency in medicine at the West Los Angeles Veterans Administration Hospital and completed his cardiology and interventional cardiology fellowship at Cedars-Sinai.
Close
Dr. A B Gopalamurugan
Dr A B Gopalamurugan
Dr A B Gopalamurugan is well renowned internationally as a pioneering interventional cardiologist and electrophysiologist who was a London based consultant cardiologist for some years before moving to India to set up Transcatheter Valve services in India in 2015.
He started India’s first TAVR with the Evolut R valve platform in 2015 making that patient the longest living TAVR patient ever in India to date. He started India’s first Transcatheter Mitral Valve Replacement (TMVR) programme in 2016 making that patient the longest living TMVR patient in India to date. He went on to start India’s first Transcatheter Tricuspid Valve Replacement (TTVR) programme in 2016 and subsequently started 14 of India’s first Transcatheter heart valve treatments including India’s first Transcaval TAVR, India’s Basilica, India’s first Lampoon, India’s first Sesame, India’s first TMVR in MAC program and several others.
He has contributed to three of the world’s first TAVR procedures including the first-in-man successful
Transeptal TMVR (published in JACC) and he holds a Guinness world record in the field of TAVR. He is the founder and course director of India’s national Transcatheter Valve course/conference namely “India Valves” which is the largest attended Transcatheter valve event of the country. It is conducted in the first weekend of September every year. He currently works between Chennai, Mumbai and London where his private offices are based.
Close
Prof. Gilbert Tang
Prof. Gilbert Tang
Gilbert H. L. Tang, MD, MSc, MBA, FRCSC, FACC, FSCAI
Vice Chair of Innovation, Department of Cardiovascular Surgery, Mount Sinai Health System.
Surgical and Academic Director, Structural Heart Program, Mount Sinai Health System.
Director, Mitral and Tricuspid Structural Interventions, Mount Sinai Health System.
Director, Structural Heart Program Education, Mount Sinai Fuster Heart Hospital.
Professor of Medicine (Cardiology) and Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai.
@GIlbertTangMD
As an interventional surgeon, Dr. Tang has performed >4000 structural heart interventions (including >600 mitral and tricuspid procedures) and is a world expert in the lifetime management after TAVR (redo TAVR and TAVR explant), transcatheter mitral and tricuspid interventions, and 3D intracardiac echo. Dr. Tang has pioneered several techniques in TAVR (cusp overlap, commissural alignment) that have become the standard practice. He serves on committees in the Heart Valve Collaboratory, PCR, and several clinical trials, and is the Principal Investigator in the global EXPLANT-TAVR, EXPLANTORREDO-TAVR, and CUTTING-EDGE registries. Dr. Tang is the Editor-in-Chief for JACC Case Reports, a 4-time recipient of the Simon Dack Award for JACC, a FRCSC, FACC and the first surgeon to be a FSCAI, as well as a member of the AATS, STS and AHA. He has published >200 articles, lectured and trained many heart teams around the world, owns a YouTube channel and has >19,000 followers on Twitter/X and Linkedin. Dr. Tang obtained his BA from Harvard University and MD from University of Toronto. Dr. Tang completed his cardiac surgery residency training at the University of Toronto and also a Masters of Science there and an MBA at Harvard. During his spare time he enjoys spending it with his lovely wife Lydia and his 2 boys: Alexander, aged 7 and Julian, aged 4.
Close
Dr. Ravinder Singh Rao
Dr. Ravinder Singh Rao
Ravinder Singh Rao MD,DM,FACC
Chairman RHL Heart Center
Visiting Cardiologist, Lilavati Hospital Mumbai
Chairman RHL Heart Center
Visiting Cardiologist, Lilavati Hospital Mumbai
Interventional Cardiologist and Structural heart disease Specialist.
Course Director, India Valves
Interventional Cardiology Fellowship,
Mount Sinai Hospital, New York, USA
Structural Heart Disease Fellowship,
Washington University School of Medicine, St Louis, USA.
RHL Heart Center, Rajasthan Hospital, Jaipur, India
Close
Dr. Duk-Woo Park
Dr. Duk-Woo Park
Division of Cardiology, ASAN MEDICAL CENTER
University Of College Of Medicine
388-1 Poongnap-dong, Songpa-gu, 138-736, Seoul, Korea
Tel; (82)-2-3010-3995, Fax; (82)-2-475-6898
dwpark@amc.seoul.kr; dwpark3995@gmail.com
PROFILE
Dr. Duk-Woo Park is now a tenured Professor in the Division of Cardiology at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Dr. Duk-Woo Park graduated from Kyoung-Hee Medical College and received medical degree from Kyoung-Hee Medical College and received M.S., Ph.D., degree from University of Ulsan College of Medicine. Dr. Duk-Woo Park subsequently did his Internal Medicine residency, Chief Residency, and Cardiology fellowship at the Asan Medical Center.
Dr. Duk-Woo Park is now responsible for the following important positions:
- Deputy Editor of “JACC Asia” Journal,
- Director of Scientific, Korean Society of Interventional Cardiology (KSIC),
- A member of Editorial Board, Circulation: Cardiovascular Interventions,
- An Executive Director, CardioVascular Research Foundation,
- Course Director, Scientific Director, TCTAP International Scientific Conference
- Course director, Scientific Director, AP Valves International Scientific Conference
- Course director, Scientific Director, Complex PCI International Scientific Conference
As Dr. Duk-Woo Park has been interested in conducting research covering all aspects of coronary artery disease and valvular heart disease, he has published approximately 420 SCI papers so far. Dr. Duk-Woo Park’s primary research interest has been in medical care of patients with ischemic heart disease, coronary revascularization treatments (percutaneous coronary intervention [PCI] or coronary bypass surgery), PCI for left main disease, transcatheter valve interventions, antiplatelet therapies, cardiovascular biomarker, and stent studies. Dr. Duk-Woo Park has been the Investigator of many clinical trials conducted in the Asan Medical Center, Seoul, Korea. Dr. Duk-Woo Park has major contributions as the principal (first or corresponding) authors in top medical journals (4 NEJM, 1 Lancet, 1 JAMA, 8 Circulation, 19 JACC, 2 EHJ, and 1 JAMA Cardiology) within last 20 years. Dr. Duk-Woo Park was awarded with Douglas P. Zipes Distinguished Young Scientist Award at the 2012 ACC (American College of Cardiology), Chicago, IL, United States (he was the first scientist from the Asia-Pacific region to receive this honor).
EDUCATION
2004-07 Ph.D., University of Ulsan College of Medicine, Seoul, KOREA
2002-04 M.S., University of Ulsan College of Medicine, Seoul, KOREA,
1992-98 M.D., B.S., University of Kyoung-Hee Medical College, Seoul, KOREA
POSTGRADUATE TRAINING
2020~Present Professor (tenure), Department of Cardiology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, KOREA
2014~2019 Associate professor, Department of Cardiology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, KOREA
2012-2013 Clinical Research Fellowship (2012–2013): Duke Clinical Research Institute (DCRI),
Durham, NC, USA
2009~2014 Assistant professor, Department of Cardiology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, KOREA
2007-09 Clinical Assistant Instructor, Department of Cardiology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, KOREA
2004-06 Clinical Fellow, Department of Cardiology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, KOREA
1999-2003 Resident Physician, Internal Medicine, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, KOREA
1998-1999 Intern Physician, Internal Medicine, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, KOREA
HONORS AND AWARDS
2023 The 21th Pfizer Medical Research Award, Seoul, Korea
2020 Best Research Professor Award, University Ulsan College of Medicine, Korea
2014 The 7th Asan Award in Medicine (Award for Young Medical Scientists)
2012 Douglas P. Zipes Distinguished Young Scientist Award,
at the 2012 ACC (American College of Cardiology), Chicago, IL, USA
2011 Best Research Professor Award, University Ulsan College of Medicine, Korea
2010 The 20th Wunsch Medical Award, Young Investigator Award, Seoul, Korea
2010 Outstanding Research Award, Angioplasty Summit, TCT Asian-Pacific
2009 Outstanding Research Award, Angioplasty Summit, TCT Asian-Pacific
2008 Outstanding Research Award, Angioplasty Summit, TCT Asian-Pacific
2009 The 42nd Yuhan Medical Research Award, Seoul, Korea
Close
Dr. Mathew R. Williams
Dr Mathew R. Williams
Mathew R. Williams, MD
Chief, Division of Adult Cardiac Surgery, Department of Cardiothoracic Surgery, NYU Langone.
Leads the NYU Langone Heart Valve Center.
Mat Williams, MD, is a world-renowned valve specialist and the first to be trained in both cardiac surgery and interventional catheter-based techniques. He has completed over 5,000 transcatheter aortic valve procedures—more than any other surgeon in the nation. Under Dr. Williams’ leadership, his team remains at the forefront of testing innovative technologies, to improve treatment for patients with heart valve disease. His work in the PARTNER I randomized landmark study comparing conventional open heart surgery using a Transcatheter Aortic Valve Replacement (TAVR) was groundbreaking. It played a pivotal role in gaining FDA approval for the device and the procedure. Dr. Williams continues to serve as the primary investigator for several US and international research studies for the aortic and mitral valve space. Many of the studies he has participated in have transformed the field of medicine and provided patients with more viable options to treat their valve disease.
Dr. Williams received his undergraduate degree from Columbia College, Columbia University NY and his MD from Medicine
College of physicians and Surgeons, Columbia University.
Postdoctoral Training
- Residency in General Surgery- UCLA Medical School, Los Angeles, CA
- Research Fellowship in Cardiothoracic Surgery, NYP Columbia University –
- Residency in General Surgery, Department of Surgery, NYP Columbia
- Residency in Cardiothoracic Surgery, Department of Surgery, NYP Columbia
- Fellowship in Interventional Cardiology, NYP Columbia
Member: American Association for Thoracic Surgery, Cardiothoracic Surgery Network
International Society for Minimally Invasive Cardiothoracic Surgery, The Society of Thoracic Surgeons, ACC
Close
Dr. Rishi Puri
Dr Rishi Puri
Rishi Puri, MD, PhD, FRACP, is a coronary and structural interventional cardiologist at the Cleveland Clinic. He is also an Associate Professor of Medicine and Medical Director of the Angiography and IVUS Core Laboratory. He completed his clinical and academic training in Adelaide (Sth Australia), Cleveland (USA), Quebec City (Canada), Rennes (France), and Zurich (Switzerland).
Rishi has published over 420 original manuscripts in high-impact journals across a broad topic base including transcatheter structural heart interventions for valvular heart disease and heart failure, atherosclerosis progression-regression and plaque imaging, and coronary physiology/pharmacology. He is actively involved in developing novel device-based technologies in the coronary, structural heart disease and interventional heart failure spaces, has co-founded and advises a range of medical start-up companies and larger strategics.
He currently serves as global co-PI for the TRICAV-1 and TRICAV-2 FDA pivotal trial testing a bi-caval stenting system for patients with severe TR, the ADVANCE-DCB FIM trial of a dual API nanoparticle drug-eluting balloon in de novo coronary lesions, and is on the global steering committees of a range of pivotal trials in the aortic and mitral valve therapy space. Rishi is an Australian native, and enjoys his spare time traveling, road cycling, trail running and XC skiing.
Close
Dr Kent So
Dr Kent So
Dr Kent So graduated from the Faculty of Medicine, Chinese University of Hong Kong. He received the prestigious Sir David Todd Scholarship to further his advanced structural heart intervention training at Henry Ford Hospital in USA. He is currently working as the Director of Structural Heart Interventions at the Prince of Wales Hospital, and Clinical Assistant Professor in the Department of Medicine and Therapeutics at the Chinese University of Hong Kong. He has been widely published in the field of structural heart interventions including device and technique innovation. He is now serving as the Associate Editor for the JACC: Case Report. He is also a global physician proctor of numerous structural heart interventions including different TAVI devices, M-TEER, T-TEER and LAAO devices. His clinical and research interests include transcatheter aortic valve implantation, percutaneous mitral and tricuspid valve repair or replacement, alternative access and closure, cardiogenic shock and mechanical circulatory support.
Close
Prof Mohamed Abdel-Wahab
Professor Mohamed Abdel-Wahab
Professor Mohamed Abdel-Wahab is currently holding the position of Senior Consultant Cardiologist and Head of the Structural Heart Disease Department at the Leipzig Heart Center, and is a Professor of Interventional Cardiology at the University of Leipzig – Germany. The Leipzig Heart Center is one of the largest centers for cardiovascular disease management in Europe. He is leading clinical and research programs in the field of transcatheter valve replacement and complex coronary interventions.
Before he moved to Leipzig, Abdel-Wahab was leading the coronary and structural heart disease program at the Heart Center of the Segeberger Kliniken in Bad Segeberg – Germany. He was presented the 2013 Publication Award of the Working Group on Interventional Cardiology of the German Society of Cardiology and the 2015 Andreas Grüntzig Award of the German Society of Cardiology.
Professor Abdel-Wahab was a nucleus member of the Working Group on Interventional Cardiology of the German Society of Cardiology, and is a Fellow of the European Society of Cardiology, a member of several international academic boards, and has published more than 250 papers in the field of interventional cardiology in peer review journals.
Close
Dr Philippe Genereux
Dr Philippe Genereux
An internationally recognized leader in structural heart disease, Dr. Généreux has been a practicing interventional cardiologist for more than 15 years. He is the director of the structural heart program at Morristown Medical Center, has served as the primary or co-investigator on more than 20 clinical trials, and has published more than 350 articles in peer-reviewed journals. He is currently the principal investigator of the EARLY TAVR trial and the PROGRESS trial, two major studies in the field of aortic valve disease. A celebrated clinical researcher since the beginning of his career, he was awarded the prestigious Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and has been named a Highly Cited Researcher by the Clarivate™ Web of Science Group for the last four years.
Dr. Généreux is also involved in multiple early-stage companies in the field of interventional cardiology and heart failure. He received his medical degree from the Université de Montréal, Montréal, Québec, Canada, his cardiology and interventional cardiology degrees from Université de Sherbrooke and Sacré-Coeur Hospital, Montreal, Canada, and performed his advanced interventional cardiology and structural heart fellowship at Columbia University and Cardiovascular Research Foundation, in New York city.
Close